Subscibe to DEAL OF THE DAY

Diabetic Digest - July 19, 2017


I'm a bit bummed out. I've put on a little weight in the last couple of weeks, but at least I know why.

I've been stress eating because my brother's wedding was this past weekend and the whole family was going crazy. Weddings are never not stressful; sorry for the double negative.

It's only 5 or 6 pounds, no big deal. Yet, I can't help think of how easy it can be to ruin all of the progress, of getting in shape and dropping some poundage, with some potato chips and a few bowls of No Sugar Added Ice Cream.

I'm getting back on the straight and narrow, but I have to say that it's much harder than I thought. Wish me luck.


P.S. Did you miss an issue? You can read every issue from the Gophercentral library of newsletters on our exhaustive archives page. Thousands of issues, all of your favorite publications in chronological order. You can read AND comment. Just click GopherArchives

Comments? Questions? Email Steve

*-- Diabetic News --*

New trial will examine type 2 diabetes drug's effect on kidney function

Researchers are investigating the efficacy of sodium glucose co-transporter 2 inhibitors, a new class of drugs to treat type 2 diabetes, on kidney function.

Type 2 diabetes is known to have damaging effects on the kidneys and can result in kidney failure requiring dialysis or kidney transplant.

An ongoing second-phase drug trial called the CANVAS-R trial is testing the effects of canagliflozin, a sodium glucose co-transporter 2, or SGLT2, inhibitor in slowing the decline of kidney function in type 2 diabetes patients.

"CANVAS-R will greatly enhance our knowledge of the effects of canagliflozin on renal disease," Professor Bruce Neal of the George Institute of Global Health at the University of Sydney, Australia, lead author of the study, said in a press release. "In conjunction with the ongoing CANVAS trial, the data will also allow us to assess effects on hard vascular outcomes. The completion of the CANVAS program should approximately double the information we have about the effects of the SGLT2 inhibitor class on vascular disease."

The CANVAS study is examining canagliflozin's efficacy in reducing the risk of cardiovascular disease and major adverse cardiac events in type 2 diabetes patients.

The CANVAS-R study results will be combined with the CANVAS results to give doctors and patients recommendations on the use and benefits of canagliflozin.

The study was published in Diabetes, Obesity and Metabolism.

*-- Diabetic News --*


6 boneless, skinless chicken breasts, pounded thin
4 cups ice water and ice
4t salt
3/4 cup ground pecans
2 whole eggs
2T milk
2T honey
1/2t salt
1/2t black pepper, course ground fresh

DIRECTIONS: Marinate the chicken breasts in iced salt water for 1/2 hour. Beat milk with honey, then add beaten edds, salt and fresh ground pepper. Put egg wash in one shallow bowl, and pecan meal in another. Dip each chicken breast in the egg wash, then into the pecan meal and pat the meal into the breast to form a crust. Place the breasts in a shallow baking pan that has been sprayed with cooking spray, and bake for 35 minutes at 375, or until the breasts are done through.

Yield: 6 Servings

Category: Chicken, Meats, Main Courses


Missed an Issue? Visit the Diabetic Digest Archives